Upstream / Downstream

Explore pathways related to this product.

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

To Purchase # 8857SC

8857SC 10 µg (With Carrier) $199.00
8857SF 10 µg (Carrier Free) $199.00
$ 0. 00

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Source / Purification

Recombinant mouse His6IL-6 (mHis6IL-6) Phe25-Thr211 (Accession #NP_112445) was expressed in human 293 cells at Cell Signaling Technology.

Product Description

Purity:

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant mHis6IL-6. All lots are greater than 98% pure.


Molecular Formula:

Recombinant N-terminally His6-tagged mIL-6 has a calculated MW of 24,311. DTT-reduced and non-reduced protein migrate as 31-36 kDa polypeptides. Lower mobility and heterogeneity in SDS-PAGE are due to glycosylation. The expected amino terminus of recombinant mHis6IL-6 was verified by amino acid sequencing.


Bioactivity:

The bioactivity of recombinant mIL-6 was determined in a B9 cell proliferation assay. The ED50 of each lot is between 0.5 and 5 pg/ml.


Endotoxin:

Less than 0.01 ng endotoxin/1 μg mHis6IL-6.


Product Usage Information

Formulation:

With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg mHis6IL-6. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.


Storage: Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles. Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

IL-6 is a potent inducer of the acute phase response and is produced by T cells, macrophages, fibroblasts, endothelial, and other cells (1,2). IL-6 induces proliferation and differentiation and acts on B cells, T cells, thymocytes, among others. IL-6 in concert with TGF-β is important for developing Th17 responses. IL-6 binds to IL-6Rα and through this association induces gp130 homodimerization (1). gp130 homodimerization triggers the Jak/Stat cascade and the SHP2/MAPK (Erk) cascade (1,3,4). IL-6 also forms a complex with an IL-6Rα splice variant that is non-membrane associated (3). This IL-6/soluble IL-6Rα complex can activate the gp130 signaling pathway on cells that express gp130, but not IL-6Rα (3). Research studies have shown that IL-6 may contribute to metastatic breast cancer by increasing expression of proangiogenic VEGF (5).


1.  Heinrich, P.C. et al. (1998) Biochem J 334 ( Pt 2), 297-314.

2.  Heinrich, P.C. et al. (1998) Z Ernahrungswiss 37 Suppl 1, 43-9.

3.  Jones, S.A. (2005) J Immunol 175, 3463-8.

4.  Jenkins, B.J. et al. (2004) Mol Cell Biol 24, 1453-63.

5.  Hong, D.S. et al. (2007) Cancer 110, 1911-28.


Entrez-Gene Id 16193
Swiss-Prot Acc. P08505


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
PathScan® is a trademark of Cell Signaling Technology, Inc.